48 completed, 14 unknown, 13 terminated, 11 recruiting. 54 Phase 2, 35 Phase 3, 19 Phase 1, 6 Not applicable, 2 Early Phase 1.
Follow Lomustine: new trials by email Literature Review of Lomustine trials Research Report on Lomustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations Vorasidenib, Lomustine - Recurrent Glioma, IDH-mutant Gliomas | Phase 1 | Not yet recruiting | Megan Mantica | 36 | 2026-11-30 | 2026-10-22 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment Lomustine, Anlotinib - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Yayi He | 46 | 2026-06-01 | 2026-06-08 |
| A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma L19TNF, L19TNF and TMZ, L19TNF and CCNU - Glioma | Phase 2 | Not yet recruiting | Philogen S.p.A. | 52 | 2026-01-30 | 2025-08-13 |
| Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma TLX-101-Tx + Lomustine, TLX101-Tx - Neoplastic Disease, Glioblastoma | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 50 | 2025-11-02 | 2026-08-11 |
| Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma Laser interstitial thermal therapy, Lomustine - Glioblastoma | Phase 1 | Recruiting | University of California, Davis | 25 | 2025-10-01 | 2026-09-28 |
| Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma Temozolomide, Lomustine - Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma | Phase 3 | Recruiting | Vastra Gotaland Region | 200 | 2025-02-01 | 2026-04-13 |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-11-03 |
| Lerapolturev (PVSRIPO) in GBM Lerapolturev, Lomustine Pill - Recurrent Supratentorial Glioblastoma | Phase 2 | Recruiting | Darell Bigner | 92 | 2024-07-15 | 2026-07-20 |
| A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence L19TNF, Lomustine - Glioblastoma | Phase 2 | Active not recruiting | Philogen S.p.A. | 90 | 2024-05-22 | 2026-04-21 |
| Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study Lomustine, Reirradiation - First Progression of Glioblastoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 411 | 2024-03-15 | 2026-06-08 |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM SonoCloud-9 (SC9), Carboplatin, Lomustine - Glioblastoma, Recurrent Glioblastoma | Phase 3 | Active not recruiting | CarThera | 560 | 2024-01-29 | 2026-11-05 |
| Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma Static Magnetic and Electric (sBE) device, Lomustine, Bevacizumab - Glioblastoma, Recurrent Glioblastoma | Not applicable | Withdrawn | Varun Monga, MD | 2023-04-01 | 2023-04-21 | |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss Audiometric Test, Auditory Brainstem Response, Biospecimen Collection - Childhood Medulloblastoma | Phase 3 | Recruiting | Children's Oncology Group | 225 | 2023-02-20 | 2026-08-25 |
| The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) Re-resection, Temozolomide, Lomustine - Glioblastoma, Glioblastoma Multiforme | Recruiting | Jasper Gerritsen | 464 | 2023-01-01 | 2024-02-28 | |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma Sonidegib, Cisplatin, Lomustine - Medulloblastoma | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 20 | 2022-11-11 | 2025-10-23 |
| Tofacitinib in Recurrent GBM Patients Tofacitinib 10mg, Temozolomide, Lomustine - Glioblastoma | Phase 3 | Completed | University of Texas Southwestern Medical Center | 18 | 2022-10-07 | 2026-06-29 |
| Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma Lomustine, Romiplostim - First Progression of MGMT Promoter-methylated Glioblastoma | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2022-09-13 | 2023-05-24 | |
| Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression Onfekafusp alfa, Lomustine - Glioblastoma | Phase 1 | Withdrawn | Philogen S.p.A. | 2022-06-01 | 2024-04-08 | |
| Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma Lomustine, Imipramine Hydrochloride - Glioblastoma | Phase 2 | Recruiting | The University of Texas Health Science Center at San Antonio | 25 | 2022-05-25 | 2025-08-27 |
Showing 20 of 105. Sign in to see all of them.
Glioblastoma (51) · Brain Neoplasms (25) · Central Nervous System Neoplasms (22) · Astrocytoma (17) · Glioma (16) · Medulloblastoma (11) · Neoplasms (8) · Lymphoma (7) · Oligodendroglioma (7) · Gliosarcoma (6) · Recurrence (6) · Burkitt Lymphoma (2) · Ependymoma (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2)
Children's Oncology Group (7) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Case Comprehensive Cancer Center (4) · M.D. Anderson Cancer Center (4) · Philogen S.p.A. (4) · Eli Lilly and Company (3) · Memorial Sloan Kettering Cancer Center (3) · Radiation Therapy Oncology Group (3) · Alliance for Clinical Trials in Oncology (2) · Children's Cancer and Leukaemia Group (2) · Isarna Therapeutics GmbH (2) · Massachusetts General Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University Hospital, Bonn (2) · Universitätsklinikum Hamburg-Eppendorf (2)
United States (64) · France (23) · Germany (23) · Canada (22) · Netherlands (21) · Italy (17) · Spain (17) · Switzerland (17) · Belgium (16) · Austria (15) · United Kingdom (14) · Australia (13) · Sweden (8) · Poland (6) · Czechia (5)
Scot C. Remick, MD (4) · Barry Pizer, MD (2) · David Ellison, MD (2) · Frank Saran, MD (2) · Jan C. Buckner, MD (2) · Roger Taylor, MD (2) · Alfred Reiter, MD (1) · Amar Gajjar, MD (1) · Anatolij D Namgaladze, Master (1) · Andrew B Lassman, MD (1) · Annick Desjardins, MD, FRCPC (1) · Arnaud Pigneux, MD, PhD (1)
PMID 35731991, PMID 40967259, PMID 11586105, PMID 12525516, PMID 15234047, PMID 16782910, PMID 16782911, PMID 16943538, PMID 17549014, PMID 18089866, PMID 18089867, PMID 18371182, PMID 18497327, PMID 18976072, PMID 19224764, PMID 19783377, PMID 19901104, PMID 20124186, PMID 20160062, PMID 20694800, PMID 20725730, PMID 20820870, PMID 20855843, PMID 21246521, PMID 21636711, PMID 21914791, PMID 22665535, PMID 22851558, PMID 23071237, PMID 23071247, PMID 23269986, PMID 24327518, PMID 24419119, PMID 24947255, PMID 24969797, PMID 26254812, PMID 26346136, PMID 26902851, PMID 27050206, PMID 27252174, PMID 27424289, PMID 27744512, PMID 27843136, PMID 27863192, PMID 28039367, PMID 28053024, PMID 28672195, PMID 29077941, PMID 29141164, PMID 29383130
P30CA043703 (4), U10CA180886 (3), 2009 (2), 2014 (2), 2023 (2), U10CA098543 (2), 2018 (1), 2025 (1), P30CA006973 (1), P30CA008748 (1), P30CA016672 (1), P30CA093373 (1), P30CA138292 (1), R01CA129371 (1), R01CA229646 (1)